research reports and media, page-498

I know you understand this already PZ99 but for the benefit of others...while this is true about the geographical limitation to the Bene/PAR exclusivity agreement, PAR still have patent protection for the treatment of BMEL with iPPS in the US, EU, China etc etc. Where BMEL is diagnosed, no competitor will be able to provide iPPS (manufactured by Bene or by anyone else who manages to come up with another FDA-approved iPPS treatment) for it's treatment - at least without facing injunction from PAR.

I'd encourage anyone with an interest in PAR to fully understand it's patent position, as this is bound to become the centre of risk/reward determination in the years to come - assuming the drug's safety and efficacy results are pretty much similar in American human bodies as they have been in Australian human bodies to date (and that no-one stuffs-up something in the remaining trials).